RxDoctor Payments Data

Jimmie Cannon, MD

Cardiovascular Disease · Jasper, GANPI 1033182043

Payments from drug & device makers

$15,483in general payments, 2019–2025

Across 82 payments — averaging $188.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$14K
  • Amgen$272
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$147
  • Johnson & Johnson$132
  • E.r. Squibb & Sons, L.L.C.$92
  • Pfizer$62
  • plus $364 from 13 others

What the payments were for

  • Speaking & faculty fees$13,52587%
  • Travel & lodging$3382%
  • Food & beverage$1,60310%
  • Education$170%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,483 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$83,908
Medicare patients
889
Services billed
1,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban553$576,236
Repatha SureclickEvolocumab183$148,665
XareltoRivaroxaban103$115,303
EntrestoSacubitril/Valsartan86$98,754
JardianceEmpagliflozin34$42,935
Praluent PenAlirocumab38$31,083
FarxigaDapagliflozin Propanediol11$18,286
Metoprolol Succinate700$9,403
VascepaIcosapent Ethyl15$8,159
Flecainide Acetate164$5,989
Rosuvastatin Calcium551$5,886
Potassium Chloride304$4,526
Carvedilol582$4,479
Ezetimibe169$3,264
Nebivolol Hcl53$2,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$576,236553 claims
Johnson & JohnsonXarelto$132$115,303103 claims
NovartisEntresto$14,414$98,75486 claims
Boehringer IngelheimJardiance$55$42,93534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Jasper

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →